Abivax S.A.
ABVXAbivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Drugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Mar 15, 2026
11dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
ABX464 Phase 2 Results Expected
Primary completion for ABX464 trial (NCT05177835) in Ulcerative Colitis
Source2 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
ABX464
Ulcerative Colitis
ABX203 therapeutic Hepatitis B vaccine treatment arm
Chronic Hepatitis B
Obefazimod
Moderately to Severely Active Crohn Disease
ABX464 100 mg
Ulcerative Colitis
ABX464 150mg
HIV Infections
ABX464 50mg
Rheumatoid Arthritis
ABX196
Carcinoma, Hepatocellular
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABX464 | Phase 3 | Ulcerative Colitis | - | - |
ABX203 therapeutic Hepatitis B vaccine treatment arm | Phase 3 | Chronic Hepatitis B | - | - |
Obefazimod | Phase 2 | Moderately to Severely Active Crohn Disease | - | - |
ABX464 100 mg | Phase 2 | Ulcerative Colitis | - | - |
ABX464 150mg | Phase 2 | HIV Infections | - | - |
ABX464 50mg | Phase 2 | Rheumatoid Arthritis | - | - |
ABX196 | Phase 2 | Carcinoma, Hepatocellular | - | - |